| Type | Valeur |
|---|---|
| cik | 0001610853 |
| ticker | HSDT |
| Date | Type | Insider | Quantité | Prix | Signaux |
|---|---|---|---|---|---|
| 21 mai 2026 | GRANT_AWARD | Lee Michel Kai Tai | 6 360 | 0.00 USD | |
| 21 mai 2026 | GRANT_AWARD | Lee Michel Kai Tai | 18 564 | 0.00 USD | deriv |
| 21 mai 2026 | GRANT_AWARD | Mello Sergio | 6 360 | 0.00 USD | |
| 21 mai 2026 | GRANT_AWARD | Mello Sergio | 18 564 | 0.00 USD | deriv |
| 21 mai 2026 | GRANT_AWARD | STRAW EDWARD M | 6 360 | 0.00 USD | |
| 21 mai 2026 | GRANT_AWARD | STRAW EDWARD M | 18 564 | 0.00 USD | deriv |
| 21 mai 2026 | GRANT_AWARD | Walter Blane | 6 360 | 0.00 USD | |
| 21 mai 2026 | GRANT_AWARD | Walter Blane | 18 564 | 0.00 USD | deriv |
| 11 mai 2026 | OTHER | Fusion Summer Ltd | 1 453 277 | 0.00 USD | |
| 11 mai 2026 | EXERCISE | Chee Choon Wee | 1 109 118 | 0.00 USD | |
| 18 sept. 2025 | GRANT_AWARD | Chee Choon Wee | 2 218 236 | 0.00 USD | derivindirect |
| 11 mai 2026 | EXERCISE | Chee Choon Wee | 1 109 118 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | Favit-Van Pelt Antonella R. | 17 500 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | BUCKMAN PAUL | 2 600 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | ANDREEFF DANE | 52 400 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | Walter Blane | 2 600 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | Perkins Sherrie L | 2 600 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | MATHIESEN JEFFREY S | 26 200 | 0.00 USD | deriv |
| 02 juil. 2025 | GRANT_AWARD | STRAW EDWARD M | 2 600 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | ANDREEFF DANE | 279 715 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | STRAW EDWARD M | 10 732 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | BUCKMAN PAUL | 10 732 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | MATHIESEN JEFFREY S | 139 857 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | Perkins Sherrie L | 10 732 | 0.00 USD | deriv |
| 06 janv. 2025 | GRANT_AWARD | Favit-Van Pelt Antonella R. | 95 892 | 0.00 USD | deriv |